Thermo Fisher (TMO) continues to gain from strategic buyouts. The company’s Bioproduction business looks promising. Yet, macroeconomic issues and currency fluctuations dampen growth. The stock carries a Zacks Rank #3 (Hold) at present.Factors Driving TMO's SharesWithin the pharma and biotech end market, of late, Thermo Fisher’s biosciences and bioproduction businesses have significantly expanded their capacity to meet the global vaccine manufacturing requirements. In terms of the newest update, despite the ...

Key Points Industry and Company Overview 1. **Industry Leader**: Thermo Fisher Scientific is a global leader in life science tools and diagnostics, often considered the industry's state of the state [4]. 2. **Market Conditions**: The industry experienced improving market conditions throughout the year, with businesses and end markets being predictable [6]. 3. **Share Gain Momentum**: Despite market volatility, Thermo Fisher has continued to gain market share and raise EPS consistently [6]. Election and Industry Impact 1. **Rebalancing of Portfolios**: The election and uncertainty around HHS policy led to a rebalancing of portfolios outside of the space [16]. 2. **Business-Friendly Administration**: A more business-friendly administration is expected to benefit the industry and Thermo Fisher's business [17]. 3. **NIH Exposure**: Thermo Fisher has a low exposure to NIH funding, with approximately 7-8% of revenue indirectly affected [24]. Pharma and Biotech 1. **Market Improvement**: Pharma and biotech markets are slowly improving, with activity picking up and pipelines strengthening [47]. 2. **Investment in R&D**: Thermo Fisher has continued to invest heavily in R&D, leading to the launch of innovative products like the Astral mass spectrometer [52]. 3. **Share Gain**: Thermo Fisher has gained share in the analytical instruments segment, particularly in areas like cryo EM and separation analysis [51]. M&A and Capital Deployment 1. **M&A Environment**: Thermo Fisher is optimistic about the M&A environment, with more unknowns creating opportunities for transactions [38]. 2. **Capital Deployment**: Thermo Fisher has a long-standing capital deployment strategy, with approximately 1/3 of deployed capital allocated to share buybacks and dividends [43]. 3. **Recent Buyback**: Thermo Fisher authorized a $4 billion share buyback in September 2024 [43]. 2025 Outlook 1. **Pandemic-Related Activity**: The headwind of pandemic-related activity will be significantly reduced in 2025 [64]. 2. **Share Gain Momentum**: Thermo Fisher expects to maintain strong share gain momentum in 2025, driven by new contracts and a better track record of navigating volatility [68]. 3. **Long-Term Misconceptions**: The biggest misconception is that Thermo Fisher cannot consistently grow share, despite its clear strategy and strong earnings growth [70].

Thermo Fisher Scientific Inc. (NYSE:TMO) Wolfe 2024 Healthcare Results Conference November 19, 2024 8:00 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Doug Schenkel - Wolfe Research Doug Schenkel All right. Good morning, everybody. I'm Doug Schenkel. I lead the Life Science Tools and Diagnostics Group here at Wolfe Research. It's my pleasure to welcome all of you to the sixth annual Wolfe Annual Healthcare Conference, my first conferenc ...

I have over 15 years of experience investing and have provided research services to mid-sized hedge funds with assets under management between $100 and $500 million. I also have had a brief stint as a sell-side analyst. I am now focusing primarily on managing my own money and my purpose here is to share my views and benefit from the insights of the Seeking Alpha user community. Feel free to provide your feedback on my thesis in the comment section and I would love to have a discussion even if you have a var ...

Thermo Fisher Scientific Inc. (NYSE:TMO) Q3 2024 Earnings Conference Call October 23, 2024 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President and Chief Executive Officer Stephen Williamson - Senior Vice President and Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Rachel Vatnsdal - JPMorgan Jack Meehan - Nephron Research Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Matt Sykes - Goldman Sachs ...

For the quarter ended September 2024, Thermo Fisher Scientific (TMO) reported revenue of $10.6 billion, up 0.2% over the same period last year. EPS came in at $5.28, compared to $5.69 in the year-ago quarter.The reported revenue represents a surprise of -0.42% over the Zacks Consensus Estimate of $10.64 billion. With the consensus EPS estimate being $5.25, the EPS surprise was +0.57%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

Thermo Fisher Scientific Inc.'s (TMO) third-quarter 2024 adjusted earnings per share (EPS) of $5.28 beat the Zacks Consensus Estimate by 0.6%. However, the figure decreased 7.2% year over year.The adjusted number excludes certain expenses, including asset amortization costs and certain restructuring costs.GAAP EPS was $4.25, down 3.8% on a year-over-year basis.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, shares of TMO decreased nearly 2% in the ...

For Thermo Fisher Scientific Inc. (NYSE: TMO ), I highlighted the downturn in the pharma and biotech industry as well as weak growth in China in my previous article published in January 2024. I anticipate the overall pharmaAnalyst’s Disclosure: I/we have a beneficial long position in the shares of TMO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no b ...

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $5.25 per share. This compares to earnings of $5.69 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.57%. A quarter ago, it was expected that this maker of scientific instrument and laboratory supplies would post earnings of $5.13 per share when it actually produced earnings of $5.37, delivering a surpri ...

Exhibit 99.1 News | --- | --- | |---------------------------------------------------------------------------|--------------------------------------------------------------------------------| | | | | FOR IMMEDIATE RELEASE | | | Media Contact Information: Sandy Pound Thermo Fisher Scientific | Investor Contact Information: Rafael Tejada Thermo Fisher Scientific | | Phone: 781-622-1223 | Phone: 781-622-1356 | | E-mail: sandy.pound@thermofisher.com | E-mail: rafael.tejada@thermofisher.com | Thermo Fisher Scient ...